A groundbreaking study from Stanford Medicine and an international consortium of researchers has unveiled a potential reason why a significant portion of individuals prescribed glucagon-like peptide-1 (GLP-1) receptor agonists, a class of widely used medications for Type 2 diabetes and obesity, experience diminished effectiveness. The research suggests that specific genetic differences may lead to a phenomenon dubbed "GLP-1 resistance," where the body’s natural hormone, GLP-1, and the drugs designed to mimic it, are less potent in certain individuals. This discovery could pave the way for more personalized treatment strategies, ensuring patients receive the most effective therapies sooner.
The Rise of GLP-1 Receptor Agonists
GLP-1 receptor agonists have revolutionized the management of Type 2 diabetes and, more recently, obesity. Medications such as Ozempic, Wegovy, Mounjaro, and Rybelsus, all belonging to this drug class, have demonstrated remarkable efficacy in improving glycemic control and promoting substantial weight loss. It is estimated that over one in four individuals diagnosed with Type 2 diabetes in developed nations currently utilize these medications, reflecting their widespread adoption and therapeutic impact. The drugs function by mimicking the action of the naturally occurring GLP-1 hormone, which is released by the intestines after a meal. GLP-1 plays a crucial role in regulating blood sugar by stimulating insulin secretion, slowing gastric emptying, and reducing appetite. For weight loss, these drugs are often prescribed at higher doses than for diabetes management, leveraging their appetite-suppressing and satiety-enhancing properties.
Unveiling GLP-1 Resistance: A Genetic Link
The new research, published on March 29th in the esteemed journal Genome Medicine, centers on a newly identified genetic factor contributing to GLP-1 resistance. Approximately 10% of the population carries specific genetic variants that are now linked to this resistance. In these individuals, paradoxically, levels of the natural GLP-1 hormone are found to be higher than normal, yet they appear to exert less biological influence. This suggests a fundamental disconnect between hormone quantity and its downstream effects.
"In some of the trials, we saw that individuals who had those variants were unable to lower their blood glucose levels as effectively after six months of treatment," explained Anna Gloyn, DPhil, a professor of pediatrics and genetics at Stanford Medicine and one of the study’s senior authors. "At that point, a doctor would likely change the patient’s drug regimen. Knowing ahead of time who is likely to respond would help patients get on the right drugs faster — a step toward precision medicine."
The study’s implications extend beyond diabetes management, as the effectiveness of these drugs for weight loss outcomes in individuals with these genetic variants remains an area of active investigation. While the current research focused primarily on blood sugar regulation, the hormonal pathways influencing appetite and satiety are closely intertwined with those regulating glucose metabolism.
A Decade of Research Culminates in New Insights
This comprehensive study represents the culmination of a decade of meticulous scientific inquiry, involving a multi-pronged approach that integrated human clinical trials, experiments with animal models, and extensive data analysis. The research team, co-led by Markus Stoffel, MD, PhD, professor of metabolic diseases at the Institute of Molecular Health Sciences, ETH Zurich in Switzerland, aimed to unravel the complex mechanisms underlying variable patient responses to GLP-1 therapies.
"When I treat patients in the diabetes clinic, I see a huge variation in response to these GLP-1-based medications and it is difficult to predict this response clinically," commented Mahesh Umapathysivam, MBBS, DPhil, an endocrinologist and clinical researcher at Adelaide University in Australia and a former trainee with Dr. Gloyn, who served as a lead author. "This is the first step in being able to use someone’s genetic make-up to help us improve that decision-making process."
Despite the significant advancements made, the precise biological mechanism driving GLP-1 resistance remains an elusive puzzle. "That is the million-dollar question," Dr. Gloyn acknowledged. "We have ticked off this enormous list of all the ways in which we thought GLP-1 resistance might come about. No matter what we’ve done, we’ve not been able to nail precisely why they are resistant."
The Role of the PAM Gene: A Crucial Enzyme
The focal point of the investigation was the impact of specific genetic variants within the gene encoding peptidyl-glycine alpha-amidating monooxygenase, or PAM. This enzyme is critical for the activation of a wide array of hormones in the body, including GLP-1.
"PAM is a truly fascinating enzyme because it’s the only enzyme we have that’s capable of a chemical process called amidation, which increases the half-life or the potency of biologically active peptides," Dr. Gloyn explained. "We thought, if you have a problem with this enzyme, there’s going to be multiple aspects of your biology that are not working properly."
Previous studies had already established a correlation between PAM variants and an increased prevalence of diabetes, as well as impaired insulin release from the pancreas. The research team sought to determine if these variants also interfered with the function of GLP-1, a gut hormone essential for post-meal blood sugar regulation.
Unexpected Findings in Human Trials
To test their hypotheses, researchers recruited adults without diabetes – chosen to minimize confounding factors – and administered a sugary solution. Their blood glucose levels were monitored meticulously every five minutes for a four-hour period. The prevailing expectation was that individuals carrying a particular PAM variant, known as p.S539W, would exhibit lower GLP-1 levels, perhaps due to reduced hormone stability resulting from impaired processing by the PAM enzyme.
However, the experimental results defied these expectations. "What we actually saw was they had increased levels of GLP-1," Dr. Gloyn stated, highlighting the surprising outcome. "This was the opposite of what we imagined we would find."
The researchers observed that despite elevated circulating GLP-1 concentrations in individuals with the PAM variant, there was a distinct lack of corresponding biological activity. Their blood sugar levels did not decrease as rapidly as anticipated, indicating that a greater amount of GLP-1 was required to achieve the same physiological effect. This strongly suggested a state of GLP-1 resistance.
Cross-Species Validation: From Mice to Clinical Trials
Given the unexpected nature of their findings, the research team dedicated several years to rigorously validating their observations through a variety of experimental approaches. "We couldn’t understand this, which is why we looked as many different ways as we could to see if this was a really robust observation," Dr. Gloyn remarked.
A crucial step in this validation process involved collaboration with scientists in Zurich who were studying mice genetically engineered to lack the PAM gene. These animal models exhibited a remarkable parallel to the human findings, demonstrating elevated GLP-1 levels coupled with a compromised ability to regulate blood sugar.
One of GLP-1’s significant physiological roles is to slow down gastric emptying, a process that contributes to both blood sugar control and weight management. In the PAM-deficient mice, food passed through the stomach at an accelerated rate, and treatment with GLP-1 drugs failed to effectively mitigate this rapid transit. Further investigations in these mice revealed diminished responsiveness to GLP-1 in both the pancreas and the gut. Intriguingly, the number of GLP-1 receptors in these tissues remained unchanged, ruling out receptor downregulation as the cause of resistance.
Additional experiments conducted with collaborators in Copenhagen provided further clarity. These studies indicated that the PAM defect did not interfere with the binding of GLP-1 to its receptor or the subsequent signal transduction pathways. This strongly suggested that the locus of resistance occurs further downstream in the biological cascade activated by GLP-1.
Clinical Trial Data Corroborate Genetic Impact
To ascertain the real-world clinical implications of GLP-1 resistance, the researchers delved into data from multiple clinical trials involving patients with diabetes. A meta-analysis of three trials, encompassing 1,119 participants, revealed a clear pattern: individuals carrying PAM variants exhibited a less favorable response to GLP-1 drugs. They were significantly less likely to achieve their target HbA1c levels, a key indicator of long-term blood sugar control.
Specifically, after six months of treatment, approximately 25% of participants without the PAM variants met the recommended HbA1c target. In stark contrast, only 11.5% of those with the p.S539W variant and 18.5% of those with another variant, p.D563G, achieved this goal.
Crucially, these genetic variations did not appear to influence patient responses to other widely prescribed diabetes medications, including sulfonylureas, metformin, and DPP-4 inhibitors. "What was really striking was that we saw no effect from whether you have a variant on your response to other types of diabetes medications," Dr. Gloyn emphasized. "We can see very clearly that this is specific to medications that are working through GLP-1 receptor pharmacology."
While two additional clinical trials, funded by pharmaceutical companies, did not reveal any significant differences between carriers and non-carriers, these studies utilized longer-acting formulations of GLP-1 drugs. Dr. Gloyn posited that these extended-release versions might possess the capacity to circumvent or mitigate GLP-1 resistance.
A Complex and Evolving Biological Landscape
The initial observations of GLP-1 resistance predate the widespread use of these drugs for weight management, emerging nearly a decade ago. While weight data was available in only two of the analyzed trials, the findings did not present a definitive link between PAM variants and weight loss outcomes, underscoring the need for more comprehensive data in this area.
Accessing comprehensive genetic data from ongoing and past clinical trials presents a significant hurdle. "It’s very common for pharmaceutical companies to collect genetic data on their participants," Dr. Gloyn noted. "For the newer GLP-1 medications, it would be useful to look at whether there are genetic variants, like the variants in PAM, that explain poor responders to their medications."
The precise biological underpinnings of GLP-1 resistance remain multifaceted and incompletely understood, likely influenced by an interplay of genetic and environmental factors. Dr. Gloyn drew a parallel to insulin resistance, a condition that has been extensively researched for decades yet still presents complexities. Despite the ongoing scientific exploration of insulin resistance, highly effective therapeutic interventions have been developed.
"There are a whole class of medications that are insulin sensitizers, so perhaps we can develop medications that will allow people to be sensitized to GLP-1s or find formulations of GLP-1, like the longer-acting versions, that avoid the GLP-1 resistance," she suggested, highlighting potential future therapeutic avenues.
This pioneering research involved contributions from a broad spectrum of academic institutions, including the University of Oxford, University of Dundee, University of Copenhagen, University of British Columbia, Churchill Hospital, Newcastle University, University of Bath, and the University of Exeter. Funding for this extensive project was provided by a diverse array of esteemed organizations, including Wellcome, the Medical Research Council, the European Union Horizon 2020 Programme, the National Institutes of Health (grants U01-DK105535, U01-DK085545 and UM-1DK126185), the National Institute for Health Research Oxford Biomedical Research Centre, the Canadian Institutes of Health Research, the Novo Nordisk Foundation, Boehringer Ingelheim, and Diabetes Australia. The findings represent a significant leap forward in understanding personalized medicine for metabolic disorders and hold promise for optimizing treatment strategies for millions worldwide.
